US Patent

US10702508 — Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Method of Use · Assigned to Aragon Pharmaceuticals Inc · Expires 2038-04-30 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating non-metastatic castrate-resistant prostate cancer using apalutamide, enzalutamide, or darolutamide.

USPTO Abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3012`	—	Erleada
`U-3012`	—	Erleada

Patent Metadata

Patent number: US10702508
Jurisdiction: US
Classification: Method of Use
Expires: 2038-04-30
Drug substance claim: No
Drug product claim: No
Assignee: Aragon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.